A DNA Database in the NHS: The End of Privacy?
By Helen Wallace,
Public Service Europe
| 12. 12. 2012
The government has announced plans to sequence the whole genomes of
100,000 patients in the NHS. This means every chemical letter in each person's DNA will be stored in their electronic medical records where it can be analysed statistically. Some, but not all, of the proposed group will be cancer patients and the project will also look at genetic mutations which arise in cancer cells as the cancer tumour grows.
The government says the project will be entirely voluntary as "patients will be able to opt out of having their genome sequenced without affecting their NHS care". But shifting to a system of "opt-out" rather than "opt-in" consent is hugely contentious. Opt-in consent – the international standard for patient care and research – requires people to be fully informed about how their data will be used and who will have access to it. But a new system of "presumed consent" to sharing electronic medical records with private companies was
proposed by David Cameron earlier this year. This means that when people give their samples they will not be...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...